Enzon Pharmaceuticals Inc (ENZN)
0.075
-0.01
(-11.56%)
USD |
OTCM |
May 02, 13:06
Enzon Pharmaceuticals Enterprise Value: -40.72M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | -40.72M |
| April 30, 2024 | -40.82M |
| April 29, 2024 | -40.82M |
| April 26, 2024 | -40.82M |
| April 25, 2024 | -40.48M |
| April 24, 2024 | -41.23M |
| April 23, 2024 | -41.23M |
| April 22, 2024 | -41.64M |
| April 19, 2024 | -41.64M |
| April 18, 2024 | -41.64M |
| April 17, 2024 | -41.64M |
| April 16, 2024 | -42.20M |
| April 15, 2024 | -41.46M |
| April 12, 2024 | -39.98M |
| April 11, 2024 | -39.98M |
| April 10, 2024 | -39.98M |
| April 09, 2024 | -40.16M |
| April 08, 2024 | -41.10M |
| April 05, 2024 | -41.82M |
| April 04, 2024 | -41.82M |
| April 03, 2024 | -42.19M |
| April 02, 2024 | -42.41M |
| April 01, 2024 | -41.20M |
| March 28, 2024 | -40.00M |
| March 27, 2024 | -40.00M |
| Date | Value |
|---|---|
| March 26, 2024 | -40.74M |
| March 25, 2024 | -41.67M |
| March 22, 2024 | -41.82M |
| March 21, 2024 | -41.07M |
| March 20, 2024 | -41.82M |
| March 19, 2024 | -42.56M |
| March 18, 2024 | -40.87M |
| March 15, 2024 | -40.87M |
| March 14, 2024 | -40.87M |
| March 13, 2024 | -40.81M |
| March 12, 2024 | -40.70M |
| March 11, 2024 | -41.82M |
| March 08, 2024 | -41.82M |
| March 07, 2024 | -41.06M |
| March 06, 2024 | -41.25M |
| March 05, 2024 | -40.87M |
| March 04, 2024 | -42.18M |
| March 01, 2024 | -41.25M |
| February 29, 2024 | -42.17M |
| February 28, 2024 | -41.90M |
| February 27, 2024 | -41.07M |
| February 26, 2024 | -40.70M |
| February 23, 2024 | -40.70M |
| February 22, 2024 | -40.33M |
| February 21, 2024 | -41.07M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-42.56M
Minimum
Mar 19 2024
15.47M
Maximum
Dec 29 2020
-14.88M
Average
-20.92M
Median
Jan 05 2022
Enterprise Value Benchmarks
| AIM ImmunoTech Inc | 7.080M |
| Perspective Therapeutics Inc | 990.24M |
| Protalix BioTherapeutics Inc | 64.08M |
| Electromed Inc | 141.45M |
| Armata Pharmaceuticals Inc | 155.54M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.672M |
| Total Expenses (Quarterly) | 0.216M |
| EPS Diluted (Quarterly) | 0.0113 |
| Earnings Yield | -0.93% |
| Normalized Earnings Yield | -28.10 |